Cargando…
Does Prefrontal Glutamate Index Cognitive Changes in Parkinson’s Disease?
INTRODUCTION: Cognitive impairment is a highly prevalent non-motor feature of Parkinson’s disease (PD). A better understanding of the underlying pathophysiology may help in identifying therapeutic targets to prevent or treat dementia. This study sought to identify metabolic alterations in the prefro...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039312/ https://www.ncbi.nlm.nih.gov/pubmed/35496064 http://dx.doi.org/10.3389/fnhum.2022.809905 |
_version_ | 1784694099726565376 |
---|---|
author | Buard, Isabelle Lopez-Esquibel, Natalie Carey, Finnuella J. Brown, Mark S. Medina, Luis D. Kronberg, Eugene Martin, Christine S. Rogers, Sarah Holden, Samantha K. Greher, Michael R. Kluger, Benzi M. |
author_facet | Buard, Isabelle Lopez-Esquibel, Natalie Carey, Finnuella J. Brown, Mark S. Medina, Luis D. Kronberg, Eugene Martin, Christine S. Rogers, Sarah Holden, Samantha K. Greher, Michael R. Kluger, Benzi M. |
author_sort | Buard, Isabelle |
collection | PubMed |
description | INTRODUCTION: Cognitive impairment is a highly prevalent non-motor feature of Parkinson’s disease (PD). A better understanding of the underlying pathophysiology may help in identifying therapeutic targets to prevent or treat dementia. This study sought to identify metabolic alterations in the prefrontal cortex (PFC), a key region for cognitive functioning that has been implicated in cognitive dysfunction in PD. METHODS: Proton Magnetic Resonance Spectroscopy was used to investigate metabolic changes in the PFC of a cohort of cognitively normal individuals without PD (CTL), as well as PD participants with either normal cognition (PD-NC), mild cognitive impairment (PD-MCI), or dementia (PDD). Ratios to Creatine (Cre) resonance were obtained for glutamate (Glu), glutamine and glutamate combined (Glx), N-acetylaspartate (NAA), myoinositol (mI), and total choline (Cho), and correlated with cognitive scores across multiple domains (executive function, learning and memory, language, attention, visuospatial function, and global cognition) administered to the PD participants only. RESULTS: When individuals retain cognitive capabilities, the presence of Parkinson’s disease does not create metabolic disturbances in the PFC. However, when cognitive symptoms are present, PFC Glu/Cre ratios decrease with significant differences between the PD-NC and PPD groups. In addition, Glu/Cre ratios and memory scores were marginally associated, but not after Bonferroni correction. CONCLUSION: These preliminary findings indicate that fluctuations in prefrontal glutamate may constitute a biomarker for the progression of cognitive impairments in PD. We caution for larger MRS investigations of carefully defined PD groups. |
format | Online Article Text |
id | pubmed-9039312 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90393122022-04-27 Does Prefrontal Glutamate Index Cognitive Changes in Parkinson’s Disease? Buard, Isabelle Lopez-Esquibel, Natalie Carey, Finnuella J. Brown, Mark S. Medina, Luis D. Kronberg, Eugene Martin, Christine S. Rogers, Sarah Holden, Samantha K. Greher, Michael R. Kluger, Benzi M. Front Hum Neurosci Neuroscience INTRODUCTION: Cognitive impairment is a highly prevalent non-motor feature of Parkinson’s disease (PD). A better understanding of the underlying pathophysiology may help in identifying therapeutic targets to prevent or treat dementia. This study sought to identify metabolic alterations in the prefrontal cortex (PFC), a key region for cognitive functioning that has been implicated in cognitive dysfunction in PD. METHODS: Proton Magnetic Resonance Spectroscopy was used to investigate metabolic changes in the PFC of a cohort of cognitively normal individuals without PD (CTL), as well as PD participants with either normal cognition (PD-NC), mild cognitive impairment (PD-MCI), or dementia (PDD). Ratios to Creatine (Cre) resonance were obtained for glutamate (Glu), glutamine and glutamate combined (Glx), N-acetylaspartate (NAA), myoinositol (mI), and total choline (Cho), and correlated with cognitive scores across multiple domains (executive function, learning and memory, language, attention, visuospatial function, and global cognition) administered to the PD participants only. RESULTS: When individuals retain cognitive capabilities, the presence of Parkinson’s disease does not create metabolic disturbances in the PFC. However, when cognitive symptoms are present, PFC Glu/Cre ratios decrease with significant differences between the PD-NC and PPD groups. In addition, Glu/Cre ratios and memory scores were marginally associated, but not after Bonferroni correction. CONCLUSION: These preliminary findings indicate that fluctuations in prefrontal glutamate may constitute a biomarker for the progression of cognitive impairments in PD. We caution for larger MRS investigations of carefully defined PD groups. Frontiers Media S.A. 2022-04-12 /pmc/articles/PMC9039312/ /pubmed/35496064 http://dx.doi.org/10.3389/fnhum.2022.809905 Text en Copyright © 2022 Buard, Lopez-Esquibel, Carey, Brown, Medina, Kronberg, Martin, Rogers, Holden, Greher and Kluger. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Buard, Isabelle Lopez-Esquibel, Natalie Carey, Finnuella J. Brown, Mark S. Medina, Luis D. Kronberg, Eugene Martin, Christine S. Rogers, Sarah Holden, Samantha K. Greher, Michael R. Kluger, Benzi M. Does Prefrontal Glutamate Index Cognitive Changes in Parkinson’s Disease? |
title | Does Prefrontal Glutamate Index Cognitive Changes in Parkinson’s Disease? |
title_full | Does Prefrontal Glutamate Index Cognitive Changes in Parkinson’s Disease? |
title_fullStr | Does Prefrontal Glutamate Index Cognitive Changes in Parkinson’s Disease? |
title_full_unstemmed | Does Prefrontal Glutamate Index Cognitive Changes in Parkinson’s Disease? |
title_short | Does Prefrontal Glutamate Index Cognitive Changes in Parkinson’s Disease? |
title_sort | does prefrontal glutamate index cognitive changes in parkinson’s disease? |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039312/ https://www.ncbi.nlm.nih.gov/pubmed/35496064 http://dx.doi.org/10.3389/fnhum.2022.809905 |
work_keys_str_mv | AT buardisabelle doesprefrontalglutamateindexcognitivechangesinparkinsonsdisease AT lopezesquibelnatalie doesprefrontalglutamateindexcognitivechangesinparkinsonsdisease AT careyfinnuellaj doesprefrontalglutamateindexcognitivechangesinparkinsonsdisease AT brownmarks doesprefrontalglutamateindexcognitivechangesinparkinsonsdisease AT medinaluisd doesprefrontalglutamateindexcognitivechangesinparkinsonsdisease AT kronbergeugene doesprefrontalglutamateindexcognitivechangesinparkinsonsdisease AT martinchristines doesprefrontalglutamateindexcognitivechangesinparkinsonsdisease AT rogerssarah doesprefrontalglutamateindexcognitivechangesinparkinsonsdisease AT holdensamanthak doesprefrontalglutamateindexcognitivechangesinparkinsonsdisease AT grehermichaelr doesprefrontalglutamateindexcognitivechangesinparkinsonsdisease AT klugerbenzim doesprefrontalglutamateindexcognitivechangesinparkinsonsdisease |